Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Bristol-Myers Squibb (BMS) building

BMS signs $1.74bn deal to boost immuno-oncology portfolio

Gainsaccess to Five Prime Therapeutics CSF1R antibody programme

- PMLiVE

BMS promotes Paul Biondi to head of business development

He willnow lead the development of its strategic partnerships

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

BMS recruits Jack Huston for European Lung cancer campaign

TheBoardwalk Empire actor will work with the firm on an awareness drive

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links